Literature DB >> 18792871

Effects of acute and chronic attenuation of postprandial hyperglycemia on postglucose-load endothelial function in insulin resistant individuals: is stimulation of first phase insulin secretion beneficial for the endothelial function?

A Major-Pedersen1, N Ihlemann, T S Hermann, B Christiansen, B Kveiborg, H Dominguez, D Nielsen, C Rask-Madsen, O L Svendsen, L Køber, C Torp-Pedersen.   

Abstract

The aim of the study is to determine if attenuation of postprandial hyperglycemia, by acutely and chronically enhancing postprandial insulin secretion in insulin-resistant individuals, improves the endothelial dysfunction. We assessed postoral glucose-load endothelial function in 56 insulin-resistant subjects with the Flow-Mediated-Dilation (FMD) technique. We randomized subjects to intervention/control group, and examined the acute and chronic effect of nateglinide, an oral antidiabetic drug of rapid action. In the intervention group, postoral glucose-load (post-OGL) FMD delta values deteriorated when compared to pre-OGL values, most significantly at 3 h post-OGL, on the following days: on the first study day termed "Baseline day" (p=0.04); on both days after 3 months of nateglinide treatment [with nateglinide administered on study-day "acute+chronic" (p=0.01); and without nateglinide on study-day "Closing day", p=0.001]. Post-OGL changes in the control group were nonsignificant both at Baseline and on Closing day. After a single dose of nateglinide "Acute day", post-OGL FMD deterioration was abolished. There was an increment in post-OGL FMD delta values most significant at 2 h post-OGL (p=0.02). Insulin concentrations increased while glucose concentrations decreased on study-days with nateglinide when compared to study-days without (p=<0.001 for both insulin and glucose). Comparisons for insulin and glucose concentrations between days with nateglinide, and likewise between days without, showed no significant difference. Postglucose load endothelial dysfunction can be prevented by administration of nateglinide, however, after 3 months of nateglinide treatment, this effect is abolished. Chronically increased insulin secretion could counteract the initial beneficial effect of reduced glucose excursions. We found no relationship between postprandial hyperglycemia and post-OGL FMD.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18792871     DOI: 10.1055/s-0028-1082327

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  5 in total

Review 1.  Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.

Authors:  Bianca Hemmingsen; David Peick Sonne; Maria-Inti Metzendorf; Bernd Richter
Journal:  Cochrane Database Syst Rev       Date:  2016-10-17

2.  Postprandial endothelial dysfunction in subjects with new-onset type 2 diabetes: an acarbose and nateglinide comparative study.

Authors:  Toru Kato; Teruo Inoue; Koichi Node
Journal:  Cardiovasc Diabetol       Date:  2010-03-24       Impact factor: 9.951

3.  Effect of fruit and vegetable concentrates on endothelial function in metabolic syndrome: a randomized controlled trial.

Authors:  Ather Ali; Yuka Yazaki; Valentine Y Njike; Yingying Ma; David L Katz
Journal:  Nutr J       Date:  2011-06-29       Impact factor: 3.271

4.  Effects of glucose load and nateglinide intervention on endothelial function and oxidative stress.

Authors:  Leilei Wang; Lixin Guo; Lina Zhang; Yan Zhou; Qinghua He; Zheng Zhang; Meng Wang
Journal:  J Diabetes Res       Date:  2013-04-07       Impact factor: 4.011

5.  Effects of nateglinide and rosiglitazone on pancreatic alpha- and beta-cells, GLP-1 secretion and inflammatory markers in patients with type 2 diabetes: randomized crossover clinical study.

Authors:  Glauce Cordeiro Ulhôa Tostes; Maria Rosário Cunha; Rosa Tsumeshiro Fukui; Márcia Regina Silva Correia; Dalva Marreiro Rocha; Rosa Ferreira Dos Santos; Maria Elizabeth Rossi da Silva
Journal:  Diabetol Metab Syndr       Date:  2016-01-04       Impact factor: 3.320

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.